- Home
- PHGE vs LPTX Comparison
PHGE vs LPTX Comparison
Compare PHGE & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- LPTX
- Stock Information
- Founded
- PHGE 2015
- LPTX 2011
- Country
- PHGE Israel
- LPTX United States
- Employees
- PHGE N/A
- LPTX N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHGE Health Care
- LPTX Health Care
- Exchange
- PHGE Nasdaq
- LPTX Nasdaq
- Market Cap
- PHGE 12.6M
- LPTX 11.1M
- IPO Year
- PHGE N/A
- LPTX N/A
- Fundamental
- Price
- PHGE $0.48
- LPTX $0.32
- Analyst Decision
- PHGE Strong Buy
- LPTX Hold
- Analyst Count
- PHGE 1
- LPTX 1
- Target Price
- PHGE $15.00
- LPTX N/A
- AVG Volume (30 Days)
- PHGE 389.8K
- LPTX 749.3K
- Earning Date
- PHGE 11-13-2025
- LPTX 11-12-2025
- Dividend Yield
- PHGE N/A
- LPTX N/A
- EPS Growth
- PHGE N/A
- LPTX N/A
- EPS
- PHGE N/A
- LPTX N/A
- Revenue
- PHGE N/A
- LPTX N/A
- Revenue This Year
- PHGE N/A
- LPTX N/A
- Revenue Next Year
- PHGE N/A
- LPTX N/A
- P/E Ratio
- PHGE N/A
- LPTX N/A
- Revenue Growth
- PHGE N/A
- LPTX N/A
- 52 Week Low
- PHGE $0.34
- LPTX $0.22
- 52 Week High
- PHGE $1.16
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- PHGE 50.36
- LPTX 57.28
- Support Level
- PHGE N/A
- LPTX $0.28
- Resistance Level
- PHGE $0.51
- LPTX $0.29
- Average True Range (ATR)
- PHGE 0.03
- LPTX 0.02
- MACD
- PHGE -0.03
- LPTX 0.00
- Stochastic Oscillator
- PHGE 85.12
- LPTX 98.75
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.